 |
|
Comparison of Effectiveness and Adverse Reactions between Isoniazid 300 mg and 400 mg in Korean Patients with Pulmonary Tuberculosis.
I Nae Park, Sang Bum Hong, Yeon Mok Oh, Chae Man Lim, Sang Do Lee, Younsuck Koh, Woo Sung Kim, Dong Soon Kim, Won Dong Kim, Tae Sun Shim
Tuberc Respir Dis. 2006;60(1):44-48. Published online 2006 Jan 1 DOI: https://doi.org/10.4046/trd.2006.60.1.44
|
|
Citations to this article as recorded by
 A Case Report of Isoniazid Induced Encephalopathy
Kyunghwa Cho, Kieun Hwang
Soonchunhyang Medical Science.2022; 28(1): 81. CrossRef The Patterns of Acquiring Anti-Mycobacterial Drug Resistance by Susceptible Strains of Mycobacterium tuberculosis
Kyutaeg Lee, Moo-Sang Chong
The Korean Journal of Clinical Laboratory Science.2021; 53(2): 137. CrossRef Effect of serum isoniazid level on treatment outcomes among tuberculosis patients with slow response – A retrospective cohort study
Hyung Woo Kim, Ah Young Shin, Jick Hwan Ha, Joong Hyun Ahn, Hye Seon Kang, Ju Sang Kim
Journal of Infection and Chemotherapy.2021; 27(11): 1555. CrossRef Treatment of pulmonary tuberculosis
Sang-Won Yoon, Jae Chol Choi
Journal of the Korean Medical Association.2019; 62(1): 25. CrossRef Economic Analysis of Latent Tuberculosis Infection Screening Strategies in Korea
Sang-Won Kim, Gil-Won Kang, Sam-Chul Shin, Seung-Eun Song
Health Policy and Management.2013; 23(4): 349. CrossRef
|